ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Sponsor
Dana-Farber Cancer Institute
Study ID
NCT04043845
Phase
PHASE1
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ibrutinib — DRUG
    Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
  • LY3214996 — DRUG
    LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.

Study Details

This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

Key Dates

Start date
Feb 3, 2020
Status verified
Feb 2020
Primary completion
Feb 3, 2020
Completion
Feb 3, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: LY3214996+Ibrutinib
    * LY3214996 will be administered by mouth once daily continuously throughout each treatment cycle * Ibrutinib will be administered by mouth once daily continuously throughout each treatment cycle.

Primary Outcome Measure

Dose Limiting Toxicity [ Time Frame: 42 days ]

Related Studies